Preclinical Models for Drug-Induced Liver Injury with special Focus on biomarkers involved in Pathomechanism
Drug-induced liver injury (DILI) remains a major obstacle in drug development and clinical therapy, often causing severe hepatic damage and treatment withdrawal. Experimental animal models are indispensable for elucidating DILI mechanisms, discovering biomarkers, and testing hepatoprotective agents before human trials. This overview synthesizes evidence from peer-reviewed studies on commonly used models-rats, mice, rabbits, guinea pigs, and zebrafish-exposed to hepatotoxins such as paracetamol, carbon tetrachloride, thioacetamide, methotrexate, diclofenac, isoniazid, sodium valproate, gentamicin, and carbamazepine. Dosing regimens, administration routes, exposure durations, and resulting biochemical and histopathological alterations were critically evaluated. Rats and mice predominate due to their reproducibility and physiological similarity to human liver function. Rabbits, guinea pigs, and zebrafish provide complementary advantages for specific toxicological questions, including immune-mediated injury and high-throughput screening. Collectively, these models enable robust investigation of DILI pathogenesis, biomarker validation, and preclinical assessment of safer therapeutics and hepatoprotective strategies.
Authors
- Venu Talla (ORCID: https://orcid.org/0000-0002-4261-4225)
- Kukkali Sneha
- Udutha Bharathi
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-17
- DOI
- https://doi.org/10.5281/zenodo.24301317
- Primary Topic
- Drug-Induced Hepatotoxicity and Protection
- Type
- article
- Field-Weighted Citation Impact
- 0.00